An examination of data from the Genomics Drug Sensitivity in Cancer project showed that the half maximal inhibitory concentration (IC50) values for Gefitinib (a tyrosine kinase inhibitor, TKI) and for Cetuximab (an anti-EGFR antibody) are significantly lower in basal as compared to non-basal cells (Supplementary Materials Figure S2A,B). Here, EGFR is linked to cancer.